A detailed history of Motley Fool Asset Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Motley Fool Asset Management LLC holds 11,031 shares of VRTX stock, worth $5.23 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
11,031
Previous 8,521 29.46%
Holding current value
$5.23 Million
Previous $3.56 Million 45.18%
% of portfolio
0.35%
Previous 0.25%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$392.81 - $485.53 $985,953 - $1.22 Million
2,510 Added 29.46%
11,031 $5.17 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $10.4 Million - $11.3 Million
-25,403 Reduced 74.88%
8,521 $3.56 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $10.7 Million - $11.7 Million
26,331 Added 346.78%
33,924 $14.2 Million
Q4 2023

Feb 02, 2024

BUY
$343.0 - $410.68 $123,823 - $148,255
361 Added 4.99%
7,593 $3.09 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $230,638 - $247,197
682 Added 10.41%
7,232 $2.51 Million
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $2.06 Million - $2.31 Million
6,550 New
6,550 $2.31 Million
Q4 2022

Feb 09, 2023

SELL
$285.76 - $321.48 $54,294 - $61,081
-190 Reduced 2.93%
6,303 $1.82 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $12,870 - $14,359
-47 Reduced 0.72%
6,493 $1.88 Million
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $57,565 - $71,674
-245 Reduced 3.61%
6,540 $1.89 Million
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $43,176 - $50,889
195 Added 2.96%
6,785 $1.77 Million
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $9,381 - $11,842
53 Added 0.81%
6,590 $1.45 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $66,207 - $74,091
365 Added 5.91%
6,537 $1.19 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $31,498 - $37,144
168 Added 2.8%
6,172 $1.24 Million
Q1 2021

May 11, 2021

SELL
$207.02 - $241.31 $18,424 - $21,476
-89 Reduced 1.46%
6,004 $1.29 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $105,782 - $141,081
511 Added 9.15%
6,093 $1.44 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $169,495 - $200,955
663 Added 13.48%
5,582 $1.53 Million
Q2 2020

Aug 12, 2020

BUY
$225.48 - $295.8 $140,474 - $184,283
623 Added 14.5%
4,919 $1.43 Million
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $68,121 - $84,503
-341 Reduced 7.35%
4,296 $1.02 Million
Q3 2019

Nov 12, 2019

BUY
$166.23 - $187.09 $60,175 - $67,726
362 Added 8.47%
4,637 $786,000
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $53,004 - $61,299
322 Added 8.15%
4,275 $784,000
Q1 2019

May 07, 2019

BUY
$163.73 - $194.7 $139,825 - $166,273
854 Added 27.56%
3,953 $727,000
Q4 2018

Feb 12, 2019

BUY
$151.91 - $192.21 $44,661 - $56,509
294 Added 10.48%
3,099 $514,000
Q3 2018

Nov 06, 2018

BUY
$167.73 - $192.74 $21,804 - $25,056
130 Added 4.86%
2,805 $541,000
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $61,202 - $71,383
420 Added 18.63%
2,675 $455,000
Q1 2018

May 04, 2018

BUY
$151.6 - $177.13 $341,858 - $399,428
2,255 New
2,255 $368,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Motley Fool Asset Management LLC Portfolio

Follow Motley Fool Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Motley Fool Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Motley Fool Asset Management LLC with notifications on news.